ArrowMark Colorado Holdings LLC Has $32.34 Million Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

ArrowMark Colorado Holdings LLC lessened its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 2.1% in the third quarter, HoldingsChannel.com reports. The firm owned 900,190 shares of the company’s stock after selling 19,226 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in Dyne Therapeutics were worth $32,335,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Dyne Therapeutics by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 134,334 shares of the company’s stock worth $4,825,000 after purchasing an additional 6,784 shares in the last quarter. FORA Capital LLC increased its stake in Dyne Therapeutics by 121.1% in the 3rd quarter. FORA Capital LLC now owns 18,180 shares of the company’s stock valued at $653,000 after buying an additional 9,958 shares during the last quarter. Quantbot Technologies LP bought a new stake in Dyne Therapeutics during the third quarter worth $34,000. Advantage Alpha Capital Partners LP bought a new stake in shares of Dyne Therapeutics during the 3rd quarter worth $386,000. Finally, FMR LLC boosted its stake in Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after acquiring an additional 3,707,734 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on DYN. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Oppenheimer reissued an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Morgan Stanley raised their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $50.82.

Dyne Therapeutics Stock Down 1.7 %

Shares of Dyne Therapeutics stock opened at $30.61 on Monday. The company’s fifty day simple moving average is $31.66 and its two-hundred day simple moving average is $35.44. The firm has a market cap of $3.12 billion, a PE ratio of -8.60 and a beta of 1.10. Dyne Therapeutics, Inc. has a 12-month low of $10.33 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the transaction, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. This represents a 6.38 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Cox bought 32,000 shares of the stock in a transaction dated Wednesday, September 4th. The stock was purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. This trade represents a -133.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 176,257 shares of company stock worth $6,193,718 over the last quarter. Corporate insiders own 20.77% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.